Breakout Ventures

The journey of bringing bio-based technologies from the lab to the market is anything but easy, and having a trusted guide can make all the difference.  𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐚𝐝𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐟𝐢𝐯𝐞 𝐧𝐞𝐰 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦! These industry experts will support Breakout, our portfolio, and our broader ecosystem — from diligencing investment opportunities to commercializing new tech. 𝐏𝐥𝐞𝐚𝐬𝐞 𝐣𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐰𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠: ✨ Sridhar Iyengar, PhD: Founder and Chief Strategy Officer of Elemental Machines ✨ Coco Krumme, PhD: Founder of Leeward Co ✨ Rebecca Nugent, PhD: VP of HTP Operations at Tessera Therapeutics ✨ Walter Solomon: Board Director and Advisor ✨ Ilan Zipkin, PhD: Founder and CEO of Supercede Therapeutics, Inc. Breakout Ventures is built on the theory that creative bioscience founders need more than just capital to take on the world's biggest challenges in human health and sustainability. Thank you to our venture partners, advisors, and community members for helping us build a bio-based future! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/gp4SADTe

🌟 Ready to build your career in early-stage biotech venture and entrepreneurship? Join Nucleate and a lineup of bio+tech investors and talent scouts on August 1st at 3pm to learn how to set yourself up for success. This virtual panel is designed for trainees excited to pursue careers in biotech startups and venture capital (VC). The interactive panel will feature four esteemed professionals who will share insights into their career paths, the types of roles available, and the key experiences needed to break into this rapidly-expanding field. 🔗 Register here to secure your spot: https://lu.ma/y795l12s 🎤 The panel features: Eric Dai - Investor, Dimension Natalie Estrella - Talent Partner, Cantos Rahil Haneef - Principal & Senior VP, LifeSci Search & LifeSci Partners Yusuf Uddin, PhD - Head of Talent, KdT Ventures Susanna Harris, PhD (moderator) - Director of Community, Breakout Ventures

Suited for treating conditions from cancer to rare genetic disorders—and customizable enough for precision medicine—siRNA therapies are taking the life sciences markets by storm. 𝐁𝐮𝐭 𝐡𝐨𝐰 𝐰𝐢𝐥𝐥 𝐬𝐮𝐩𝐩𝐥𝐲 𝐦𝐞𝐞𝐭 𝐝𝐞𝐦𝐚𝐧𝐝? EnPlusOne Biosciences, a Breakout Ventures portfolio company, has the answer. In an industry-first, EnPlusOne Biosciences used 𝘦𝘯𝘻𝘺𝘮𝘢𝘵𝘪𝘤 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴 to produce Leqvio®, an siRNA treatment for high-cholesterol. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🥇 Using their water-based ezRNA™ platform, EnPlusOne Biosciences completed the first known template-independent enzymatic synthesis of a fully natural siRNA length oligonucleotide (23-nt). 💊 Licensed from Alnylam Pharmaceuticals, Leqvio® currently addresses a multi-million patient population. The enzymatically-synthesized sequence is fully modified to match the FDA-approved drug. 🔬 With over 50 RNA modifications already demonstrated, the ezRNA™ platform unlocks countless possibilities for innovative drug design and development. Congratulations to the EnPlusOne Biosciences team and its co-founders Daniel Ahlstedt (COO) and Jonathan Rittichier (CSO) on reaching these tremendous milestones! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/gcsxs9rn

Congratulations to the Canaery team, whose progress in developing the world's first nose-computer interface (NCI) was recognized at this year's Trace Explosives and Drug Detection Workshop! CEO Gabriel Lavella, PhD and CTO Peter Ledochowitsch were on site in Dublin to participate in the Scientific Workshops event and receive the David Fine Innovation Award.

Women make up ~50% of the biotech workforce... but only hold ~20% of the C-suite roles. The Wall Street Journal asked "what steps would help expand gender diversity in the venture and startup ecosystem?" Highlighted in this week's WSJ Pro Newsletter, Breakout Ventures' Managing Partner and Co-Founder Lindy Morris Fishburne answered: ❛❛Forty-five percent of our investments are founded by a woman or have a female CEO because they are the best people for those roles and because social network theory is real. As a venture fund owned and managed by two female GPs, we have an advantage in meeting the best founders in the market, many of whom are women who want female investors on their boards. Increasing the number of female investors and fund managers is key to increasing support for female entrepreneurs.❜❜ Thank you to Matthew Strozier, Bureau Chief at WSJ Pro Venture Capital, for bringing these important topics to the forefront!

Understanding biology is the key to harnessing its power. Using CellChorus's TIMING technology, researchers at Indee Labs have uncovered crucial insights for improving CAR T-cell therapies. 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: ⚠ Manufacturing CAR T-cell therapies relies on inherently risky or inefficient methods, like viral transduction and CRISPR/Cas9 systems. 🛠 Indee Labs launched a scientific study to explore whether hydroporation could serve as a gentler and safer alternative for engineering cell therapies. 🔬 Uncovering behaviors at the single-cell level, the TIMING™ system from CellChorus showed hydroporation's advantages in terms of motility, resistance to AICD, and overall functionality during target cell engagement. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/g2S7JF85

Our Venture Partner Ilan Zipkin says it best -"The intersection of biological science and other tech affects a range of commercialization... convergent technology is going to be really necessary in the spinal cord field." Watch the full BiotechTV interview with Brian Orelli, PhD to learn how Breakout Ventures envisions the impact of augmenting cell therapies with the capabilities of other technologies. https://lnkd.in/gTmuxgU4

Congratulations to Parallel Bio on an exciting team expansion — Ari Gesher is joining as the Head of Technology to lead development of AI and robotics for their immune organoid platform. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 💊 Parallel Bio focuses on increasing the precision and efficiency of immunotherapy testing. Their "Clinical Trial in a Dish" platform increases success rates for drug discovery while reducing costs and reliance on animal models. 🛠 Joining the Parallel Bio team as their Head of Technology, Ari Gesher brings decades of industry experience, including leadership roles at Insight M and Palantir Technologies. 🔬 Gesher will collaborate with Co-Founders Robert M. DiFazio and Juliana L. Hilliard to streamline lab processes, create organoids, analyze and report on experiments, and develop predictive disease models from biological data. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/dr2_AGqz

Immusoft: lots of folks thought it was a crazy bold idea.. it was.. and now their science is in the clinic on the path to changing patient lives.. this is the best part of venture capitial

Our companies are literally saving lives.